Selank: Dosage, Nasal Spray and the Evidence Behind the Anxiety Claim

The short answer: Selank is a registered anti-anxiety medicine in Russia, sold there as nasal drops, and almost all of its human research comes from Russian groups linked to the institute that developed it. The core trial behind the anxiety claim enrolled 62 patients and compared Selank with a benzodiazepine, with no placebo arm¹. Selank is not approved in the United States, it is not on the list of substances US pharmacies may compound, and FDA says it "lacks important information" about its safety in people¹².

Below: what Selank is, how the Russian label doses it, what side effects have been reported, where it stands legally in the US, and why a foreign approval is not evidence you can check.

What Selank is

Selank is a seven-amino-acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro). It is built from tuftsin, a short peptide from the immune system, with a three-amino-acid tail (Pro-Gly-Pro) added. Researchers at Moscow's Institute of Molecular Genetics, which publishes much of the Selank literature, describe it as an anxiolytic with "prolonged anti-anxiety and nootropic effects" and report that it acts on GABA receptor binding in brain tissue, the same system benzodiazepines act on, though at a different site⁵.

The mechanism work is mostly in rats and cell cultures. A typical example: Selank given into the nose of rats changed levels of BDNF, a nerve growth signal, in the hippocampus⁶, and other work tracked shifts in immune-signaling genes⁸. Interesting, and a long way from proof of an effect on anxiety in people.

Nasal dosing as used in Russia

Selank is registered in Russia as 0.15% nasal drops, which is 1.5 mg of Selank per milliliter. The label, for adults with anxiety and stress-related conditions, says¹¹:

• •2 drops in each nostril, 3 times a day, which is 12 drops a day.
• •A 14-day course, which may be repeated after one to three weeks, on a doctor's advice.
• •Not for people under 18, or during pregnancy or breastfeeding, because those groups were not studied.

The label does not convert drops to milligrams. At a typical drop size of around 0.05 milliliters, 12 drops would be just under 1 mg of Selank a day. That is an estimate from drop size, not a figure on the label.

Two things are worth knowing about the doses sold outside Russia. Research-peptide vendors sell Selank as lyophilized powder for injection or in homemade-strength nasal sprays¹⁰, with doses that do not match the Russian drops and come from no trial. And no dose of Selank has been tested in a study designed to US or European regulatory standards.

The evidence behind the anxiety claim

The human studies are real, small, and published in Russian.

• •The core trial (2008). 62 patients with generalized anxiety disorder or neurasthenia: 30 received Selank, 32 received medazepam, a benzodiazepine. Anxiety improved similarly on both, and the authors reported extra anti-fatigue effects for Selank. There was no placebo group¹.
• •The immune study (2008). Patients with anxiety disorders took Selank for 14 days, and researchers measured shifts in blood immune signaling molecules².
• •Selank versus phenazepam (2014). 60 patients with anxiety disorders; the authors reported a "pronounced" anxiolytic effect lasting a week after the last dose³.
• •Selank added to phenazepam (2015). 70 patients; adding Selank to the benzodiazepine reduced some of its side effects, such as sedation and memory problems⁴.
• •A brain-scan study (2020). In 52 healthy volunteers, a single dose of Selank or Semax shifted resting brain connectivity compared with placebo. That shows the peptide does something in the brain, not that it treats anxiety⁷.

Notice what is missing. None of the treatment trials compared Selank with placebo. Each enrolled a few dozen people. The author lists include researchers from the Institute of Molecular Genetics¹³⁴. A US clinical pharmacology review in 2021 summed it up as one of the "poorly studied Russian drugs" being sold to US consumers as dietary supplements⁹.

Side effects reported

The Russian label lists two side effects, both at unknown frequency: allergic reactions, including delayed ones, and an unpleasant taste when drops run down the throat¹¹. The 2015 study reported fewer side effects with Selank added to phenazepam than with phenazepam alone⁴. Small, short trials cannot detect rare harms, and nothing has followed people on repeated courses for long.

FDA's own entry adds a different worry. It states that compounded Selank "may pose risk for immunogenicity" because peptides can clump and carry manufacturing impurities, and that the agency lacks information on safety issues in humans¹². For a vial bought online, add the basic problem that its contents are unverified: a Belgian medicines lab analyzing seized products and online offerings found Selank and Semax being sold freely as injectable powders and nasal sprays without having completed clinical trials¹⁰.

US legal status

• •Not FDA-approved for any use.
• •Not on the 503A list, the regulation naming the bulk substances pharmacies may compound. That list holds six substances, none of them peptides¹³.
• •No pending nomination. FDA lists "Selank acetate (TP-7)" in its table of withdrawn nominations¹², and Selank was not among the seven substances its advisory committee voted on in July 2026, while its usual shelf-mate Semax was¹⁴.

So there is no lawful US compounding route for Selank today. Tested athletes should run it through our prohibited-substance checker rather than assume either way.

What would settle the question

The trial that would answer whether Selank works for anxiety is not exotic. It would randomize a few hundred adults with generalized anxiety disorder to Selank, placebo, or both Selank and an established treatment; use the same standard rating scales the Russian studies used; run for at least eight weeks; and be run or replicated by a group with no stake in the drug. It would also report what happens when people stop, because the benzodiazepine comparison invites exactly that question.

Until that exists, the most a careful reader can say is that Selank has a plausible mechanism, a decades-long Russian research program, and small active-comparator trials that point in a favorable direction. That is a reasonable basis for further study. It is a thin basis for buying a vial of unknown strength from a website.

Why a Russian approval isn't evidence you can check

A registration in Russia means Russian regulators accepted the developer's file. It does not put that file in front of you. The trials are in Russian-language journals, the full data are not public, and nobody outside the developing institute's circle has repeated the key anxiety trial. That is not a judgment on Russian science; it is a statement about what a reader can verify. A US or European approval comes with a public label, a public review and placebo-controlled trials. Selank has none of those.

The same pattern runs through its stablemate: see Semax vs Selank and Semax FDA status. For how Selank compares with oxytocin and DSIP as anxiety peptides, see peptides for anxiety.

What US prescribers actually offer

Selank is rare on US prescription menus. ElitePhysiqMD sells semax and selank as monthly subscriptions, on a peptide menu whose cheapest item is $215.10 a month. Ask any seller which pharmacy compounds it and on what legal basis, since it is not on the 503A list.

The nasal sprays that US clinicians do prescribe are not anxiety drugs: LaSara sells a VIP nasal spray at $199, or $179 subscribed; AgelessRx sells sermorelin as a nasal spray from $149 a month; Auren Rx sells NAD+ as a nasal spray at $179 a month on auto-refill; CeliaRx sells PT-141 as a nasal spray at $349 a fill. None treats anxiety. If what you want is a prescribed wellness peptide from a licensed US pharmacy, our NAD+ provider rankings compare that market on price and terms; just do not expect NAD+ to do what Selank is sold to do.

Anxiety itself has well-tested treatments, psychological and medical. A clinician can help you weigh those first.